JACC:复杂PCI后确定双重抗血小板治疗时间,别忘了把手术复杂性考虑进去哦

2016-10-19 MedSci MedSci原创

目前,复杂的药物洗脱支架(DES)经皮冠状动脉介入治疗(PCI)后最佳的前期双重抗血小板治疗(DAPT)持续时间仍不清楚。来自美国的研究人员开展了一项研究,本研究根据PCI复杂程度,调查了阿司匹林和氯吡格雷DAPT长期(≥12个月)与短期(3或6个月)的疗效性和安全性。作者汇集了来自6项随机对照试验的患者水平数据,这些对照试验都研究了PCI后DAPT的持续时间。复杂PCI被定义为具有至少1个以下特

目前,复杂的药物洗脱支架(DES)经皮冠状动脉介入治疗(PCI)后最佳的前期双重抗血小板治疗(DAPT)持续时间仍不清楚。

来自美国的研究人员开展了一项研究,本研究根据PCI复杂程度,调查了阿司匹林和氯吡格雷DAPT长期(≥12个月)与短期(3或6个月)的疗效性和安全性。

作者汇集了来自6项随机对照试验的患者水平数据,这些对照试验都研究了PCI后DAPT的持续时间。复杂PCI被定义为具有至少1个以下特征:3个血管治疗,≥3个植入支架,≥3个病变治疗,分岔植入2个支架,总支架长度>60mm或慢性完全闭塞。主要有效性终点是主要不良心脏事件(MACE),定义为心脏死亡,心肌梗死或支架血栓的复合事件。主要安全终点为大出血。意向治疗是主要的分析方法。

在汇总数据集的9,577例患者中,1,680例患者(17.5%)接受了复杂PCI。总体而言,85%的患者接受了新一代DES。在中位随访时间为392天时(四分位数范围:366至710天),接受复杂PCI的患者具有更高的MACE风险(调整的风险比[HR]:1.98; 95%置信区间[CI]:1.50至2.60; p<0.0001)。在复杂PCI组(调整后的HR:0.56; 95%CI:0.35至0.89)vs 非复杂PCI组(调整HR:1.01; 95%CI:0.75至1.35; pinteraction=0.01)中,与短期DAPT相比,长期DAPT的患者MACE事件发生率显著降低。每次手术复杂性增加,长期DAPT获益性都会逐渐增加。长期DAPT与大出血风险增加有关,这在组间都是相似的(pinteraction=0.96)。通过每个治疗标志性分析的结果都是一致的。

除了其他已建立的临床风险因素,手术复杂性也是在确定DAPT的前期持续时间时应该考虑的一个重要参数。

原始出处:

Gennaro Giustino,Alaide Chieffo,Tullio Palmerini,et al.Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI,JACC,2016.10.19


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1992649, encodeId=b25a199264964, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Thu Apr 13 22:18:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853590, encodeId=b8f718535904a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 24 18:18:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325311, encodeId=636c13253119f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402163, encodeId=798d140216342, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587230, encodeId=a06f158e230d4, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149895, encodeId=788a14989561, content=学习知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Thu Oct 20 09:38:12 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149861, encodeId=237f149861da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Oct 20 08:06:21 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149750, encodeId=90b7149e508a, content=学习了!正在做这方面研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160822/IMG57BB0679D539F3056.jpg, createdBy=dc721940810, createdName=锦鹤, createdTime=Wed Oct 19 15:37:45 CST 2016, time=2016-10-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1992649, encodeId=b25a199264964, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Thu Apr 13 22:18:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853590, encodeId=b8f718535904a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 24 18:18:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325311, encodeId=636c13253119f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402163, encodeId=798d140216342, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587230, encodeId=a06f158e230d4, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149895, encodeId=788a14989561, content=学习知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Thu Oct 20 09:38:12 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149861, encodeId=237f149861da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Oct 20 08:06:21 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149750, encodeId=90b7149e508a, content=学习了!正在做这方面研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160822/IMG57BB0679D539F3056.jpg, createdBy=dc721940810, createdName=锦鹤, createdTime=Wed Oct 19 15:37:45 CST 2016, time=2016-10-19, status=1, ipAttribution=)]
    2017-04-24 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1992649, encodeId=b25a199264964, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Thu Apr 13 22:18:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853590, encodeId=b8f718535904a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 24 18:18:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325311, encodeId=636c13253119f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402163, encodeId=798d140216342, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587230, encodeId=a06f158e230d4, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149895, encodeId=788a14989561, content=学习知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Thu Oct 20 09:38:12 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149861, encodeId=237f149861da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Oct 20 08:06:21 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149750, encodeId=90b7149e508a, content=学习了!正在做这方面研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160822/IMG57BB0679D539F3056.jpg, createdBy=dc721940810, createdName=锦鹤, createdTime=Wed Oct 19 15:37:45 CST 2016, time=2016-10-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1992649, encodeId=b25a199264964, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Thu Apr 13 22:18:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853590, encodeId=b8f718535904a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 24 18:18:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325311, encodeId=636c13253119f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402163, encodeId=798d140216342, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587230, encodeId=a06f158e230d4, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149895, encodeId=788a14989561, content=学习知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Thu Oct 20 09:38:12 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149861, encodeId=237f149861da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Oct 20 08:06:21 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149750, encodeId=90b7149e508a, content=学习了!正在做这方面研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160822/IMG57BB0679D539F3056.jpg, createdBy=dc721940810, createdName=锦鹤, createdTime=Wed Oct 19 15:37:45 CST 2016, time=2016-10-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1992649, encodeId=b25a199264964, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Thu Apr 13 22:18:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853590, encodeId=b8f718535904a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 24 18:18:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325311, encodeId=636c13253119f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402163, encodeId=798d140216342, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587230, encodeId=a06f158e230d4, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149895, encodeId=788a14989561, content=学习知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Thu Oct 20 09:38:12 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149861, encodeId=237f149861da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Oct 20 08:06:21 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149750, encodeId=90b7149e508a, content=学习了!正在做这方面研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160822/IMG57BB0679D539F3056.jpg, createdBy=dc721940810, createdName=锦鹤, createdTime=Wed Oct 19 15:37:45 CST 2016, time=2016-10-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1992649, encodeId=b25a199264964, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Thu Apr 13 22:18:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853590, encodeId=b8f718535904a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 24 18:18:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325311, encodeId=636c13253119f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402163, encodeId=798d140216342, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587230, encodeId=a06f158e230d4, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149895, encodeId=788a14989561, content=学习知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Thu Oct 20 09:38:12 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149861, encodeId=237f149861da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Oct 20 08:06:21 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149750, encodeId=90b7149e508a, content=学习了!正在做这方面研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160822/IMG57BB0679D539F3056.jpg, createdBy=dc721940810, createdName=锦鹤, createdTime=Wed Oct 19 15:37:45 CST 2016, time=2016-10-19, status=1, ipAttribution=)]
    2016-10-20 flysky120

    学习知识

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1992649, encodeId=b25a199264964, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Thu Apr 13 22:18:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853590, encodeId=b8f718535904a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 24 18:18:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325311, encodeId=636c13253119f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402163, encodeId=798d140216342, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587230, encodeId=a06f158e230d4, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149895, encodeId=788a14989561, content=学习知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Thu Oct 20 09:38:12 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149861, encodeId=237f149861da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Oct 20 08:06:21 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149750, encodeId=90b7149e508a, content=学习了!正在做这方面研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160822/IMG57BB0679D539F3056.jpg, createdBy=dc721940810, createdName=锦鹤, createdTime=Wed Oct 19 15:37:45 CST 2016, time=2016-10-19, status=1, ipAttribution=)]
    2016-10-20 doctorJiangchao

    继续学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1992649, encodeId=b25a199264964, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Thu Apr 13 22:18:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853590, encodeId=b8f718535904a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 24 18:18:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325311, encodeId=636c13253119f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402163, encodeId=798d140216342, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587230, encodeId=a06f158e230d4, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Oct 21 06:18:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149895, encodeId=788a14989561, content=学习知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Thu Oct 20 09:38:12 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149861, encodeId=237f149861da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Thu Oct 20 08:06:21 CST 2016, time=2016-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149750, encodeId=90b7149e508a, content=学习了!正在做这方面研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160822/IMG57BB0679D539F3056.jpg, createdBy=dc721940810, createdName=锦鹤, createdTime=Wed Oct 19 15:37:45 CST 2016, time=2016-10-19, status=1, ipAttribution=)]
    2016-10-19 锦鹤

    学习了!正在做这方面研究

    0

相关资讯

Circulation:降低PCI围手术期心肌梗死事件发生率,坎格雷洛效果显著

坎格雷洛是一种静脉P2Y12抑制剂,被批准用于降低那些接受经皮冠状动脉介入治疗患者的围手术期缺血事件,这些患者没有预先使用过P2Y12抑制剂。在CHAMPION PHOENIX试验中,共有11145例患者随机接受坎格雷洛或氯吡格雷。研究人员使用了不同定义探讨了坎格雷洛对心肌梗死(MI)的影响,并对该试验的主要终点进行了敏感性分析。共有462例(4.2%)接受经皮冠状动脉介入治疗的患者发生一次MI事

JACC:PCI vs CABG治疗无保护的左冠脉主干病变患者的长期数据

目前,对于无保护的左主干病变(LMD)患者,经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)治疗的比较数据还缺乏统计力量,这是由于招募的患者数量较少造成的。 这项研究根据病变解剖复杂性评估了PCI和CABG治疗LMD的长期结果。 在PRECOMBAT试验中,来自荷兰的研究人员进行了LMD患者个体层面的数据汇集分析。主要心脏不良事件发生率在随访5年时进行了评估。

JACC:对于并发冠状动脉慢性完全闭塞的STEMI患者,接受额外的PCI是否有益?

10%至15%的ST段抬高心肌梗死(STEMI)患者会并发冠状动脉慢性完全闭塞(CTO)疾病(在非梗死相关动脉中存在),这增加了发病率和死亡率。来自荷兰的研究人员开展了EXPLORE试验,该试验评估了STEMI和并发CTO(在非梗死相关动脉中存在)的患者是否会受益于初次经皮冠状动脉介入治疗(PCI)后不久后直接进行CTO的PCI。从2007年11月至2015年4月,研究人员在欧洲和加拿大的14个中

JACC:房颤和PCI后临床结果之间的数据分析

目前房颤(AF)的患病率正在增加,有房颤史的患者通常接受过经皮冠状动脉介入治疗(PCI)。但目前还缺乏关于AF和PCI后临床结果之间联系的数据。来自美国密歇根的研究人员进行了一项大型,前瞻性多中心的注册研究,该研究旨在评估AF和住院时不良结果之间的联系。研究人员分析了从2011年4月到2014年12月期间的47家医院中,接受PCI的病例数据。倾向匹配的多元分析方法用来调整有AF病史和无AF病史患者

Circulation: 光学相干断层扫描优化非ST段抬高急性冠脉综合征患者介入治疗效果

由此可见,急性非ST段抬高急性冠脉综合征患者光学相干断层扫描引导PCI比血管造影引导的PCI有较高的术后血流储备分数。OCT不增加围手术期并发症、心肌梗塞或急性肾损伤。

JAMA Cardiol:PCI术后抗血小板治疗结论不一致,强调随机试验的重要性

近期有研究表明,PCI术后抗血小板治疗的安全性和有效性数据在不同分析技术中差异很大,突出随机试验的重要性。研究人员比较了PCI术后普拉格雷(Effient, Daiichi Sankyo/Eli Lilly) vs. 硫酸氢氯吡格雷的有效性和安全性,使用两种分析技术(治疗权重校正的逆概率和工具变量方法)。Jerome J. Federspiel博士和同事对11784例患者(平均年龄60岁;女性占2